The earnings call presented a positive outlook with strong revenue growth, particularly in the MedTech segment, successful product performance, and operational efficiency improvements. However, the impact of tariffs and a decline in NanoKnife capital sales were noted challenges.

Company Guidance -

Q1 2026

During the AngioDynamics Fiscal Year 2025 Fourth Quarter Earnings Call, the company provided detailed guidance for fiscal year 2026, anticipating net sales between $305 million and $310 million, reflecting a growth rate of 4% to 6% over the previous year. The MedTech segment is projected to grow by 12% to 15%, while the med device segment is expected to remain flat. The company also issued a gross margin forecast of 53.5% to 55.5%, factoring in a potential $4 to $6 million tariff impact. Absent this impact, gross margins would be in the range of 55% to 56%. Adjusted EBITDA is expected to range from $3 million to $8 million, and adjusted loss per share is projected between negative $0.35 and negative $0.25, again considering potential tariff impacts. AngioDynamics remains optimistic about being cash flow positive for the full fiscal year, emphasizing its strategic transformation and operational efficiency initiatives to support sustainable growth.

Strong Revenue Growth

Total revenue for the fourth quarter was $80.2 million, representing a growth of over 12% year-over-year. MedTech growth was over 20% and med device growth was more than 6%.

Auryon Platform Success

Auryon has delivered its sixteenth consecutive quarter of double-digit increases, with revenue reaching $15.6 million, growing 19.7% compared to last year.

Mechanical Thrombectomy Growth

The mechanical thrombectomy portfolio showed approximately 45% year-over-year growth, with AngioVac and AlphaVac contributing significantly.

Operational Efficiency

Generated positive adjusted EBITDA and over $15 million of free cash flow in the fourth quarter. Expecting $15 million in annualized savings by fiscal 2027.

NanoKnife and Regulatory Milestones

NanoKnife achieved key clinical, reimbursement, and regulatory milestones with a CPT Category I code granted for prostate and liver treatments effective January 1, 2026.

AngioDynamics (ANGO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ANGO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 02, 2025	2026 (Q1)	-0.12 / -	-0.11	―	―	―
Jul 15, 2025	2025 (Q4)	-0.12 / -0.03	-0.06	50.00% (+0.03)
Apr 02, 2025	2025 (Q3)	-0.13 / -0.08	-0.16	50.00% (+0.08)
Jan 08, 2025	2025 (Q2)	-0.11 / -0.04	-0.05	20.00% (+0.01)
Oct 03, 2024	2025 (Q1)	-0.15 / -0.11	-0.12	8.33% (<+0.01)
Jul 16, 2024	2024 (Q4)	-0.17 / -0.06	0.02	-400.00% (-0.08)
Apr 04, 2024	2024 (Q3)	-0.15 / -0.16	-0.03	-433.33% (-0.13)
Jan 05, 2024	2024 (Q2)	-0.07 / -0.05	0.01	-600.00% (-0.06)
Oct 04, 2023	2024 (Q1)	-0.13 / -0.12	-0.06	-100.00% (-0.06)
Jul 12, 2023	2023 (Q4)	0.02 / 0.02	0.01	100.00% (+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ANGO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 15, 2025	$9.63	$8.65	-10.18%
Apr 02, 2025	$9.66	$10.86	+12.42%
Jan 08, 2025	$9.40	$12.94	+37.66%
Oct 03, 2024	$7.65	$6.37	-16.73%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.